

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT		
NATURE OF CONVEYANCE:	Corrective Assignment to correct the legal entity type of the receiving party previously recorded on Reel 004806 Frame 0001. Assignor(s) hereby confirms the receiving party is a Limited Liability Company.		
CONVEYING PARTY DATA			
	Name	Formerly	Execution Date
	Nutrition 21, Inc.		11/22/2011
			Entity Type
			CORPORATION: NEW YORK
RECEIVING PARTY DATA			
Name:	N21 Acquisition Holding, LLC		
Street Address:	4 Manhattanville R.		
Internal Address:	Suite 202		
City:	Purchase		
State/Country:	NEW YORK		
Postal Code:	10577		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 8			
	Property Type	Number	Word Mark
	Registration Number:	2674646	CONTROL EATING BALANCE BODY COMPOSITION BOOST METABOLISM
	Registration Number:	2674651	CONTROL EATING BALANCE BODY COMPOSITION BOOST METABOLISM
	Registration Number:	2674652	CONTROL EATING BALANCE BODY COMPOSITION BOOST METABOLISM
	Registration Number:	2854190	DIACHROME
	Registration Number:	2948444	DIACHROME
	Registration Number:	3395499	CORE4LIFE CHROMAX
	Registration Number:	3362195	DIACHROME
	Registration Number:	3309819	PERFECT 3
CORRESPONDENCE DATA			

OP \$215.00 2674646

Fax Number: 9497609502

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Phone: 707-858-4000

Email: catherine.tolo@knobbe.com

Correspondent Name: Knobbe, Martens, Olson & Bear, LLP

Address Line 1: 2040 Main Street, 14th Floor

Address Line 4: Irvine, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER:	NUTRI.000
NAME OF SUBMITTER:	Kathleen R. Mekjian
Signature:	/Kathleen R. Mekjian/
Date:	07/09/2012

Total Attachments: 14

source=2011_11_22_Nutrition21_to_N21#page1.tif
source=2011_11_22_Nutrition21_to_N21#page2.tif
source=2011_11_22_Nutrition21_to_N21#page3.tif
source=2011_11_22_Nutrition21_to_N21#page4.tif
source=2011_11_22_Nutrition21_to_N21#page5.tif
source=2011_11_22_Nutrition21_to_N21#page6.tif
source=2011_11_22_Nutrition21_to_N21#page7.tif
source=2011_11_22_Nutrition21_to_N21#page8.tif
source=2011_11_22_Nutrition21_to_N21#page9.tif
source=2012_06_25_Recorded_Assignment_NUTRI#page1.tif
source=2012_06_25_Recorded_Assignment_NUTRI#page2.tif
source=2012_06_25_Recorded_Assignment_NUTRI#page3.tif
source=2012_06_25_Recorded_Assignment_NUTRI#page4.tif
source=2012_06_25_Recorded_Assignment_NUTRI#page5.tif

ASSIGNMENTS OF PATENTS AND TRADEMARKS

THIS ASSIGNMENT OF PATENTS AND TRADEMARKS is made effective as of November 22, 2011, by NUTRITION 21, INC. and NUTRITION 21, LLC (collectively, the "*Assignor*"), to N21 Acquisition Holding, LLC ("*Assignee*").

Assignee and Assignor are parties to an Amended and Restated Asset Purchase and Sale Agreement, entered into and effective as of November 1, 2011 (the "*Agreement*"), pursuant to which Assignee has purchased and acquired the Purchased Assets (as defined in the Agreement), including without limitation all of Assignor's worldwide right, title and interest in, to and under Assignor's registered and unregistered domestic and foreign patents and trademarks, patent applications and trademark applications, including without limitation, the patents, trademarks, patent applications and trademark applications listed on Annex A attached hereto and incorporated herein by reference (all of the foregoing being referred to herein as the "*Patents and Trademarks*"). Capitalized terms used herein, but not otherwise defined herein, shall have the meaning ascribed to them in the Agreement.

NOW, THEREFORE, for and in consideration of the mutual covenants contained herein and in the Agreement and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, conveys, assigns, transfers, delivers and grants to Assignee, and Assignee hereby accepts the sale, conveyance, assignment, transfer, delivery and grant of, all of Assignor's worldwide right, title and interest in, to and under the Patents and Trademarks, together with the goodwill of the business associated therewith and which is symbolized thereby, all rights to sue for infringement of any Patent and Trademark, whether arising prior to or subsequent to the date of this Assignment of Patents and Trademarks, and any and all renewals and extensions thereof that may hereafter be secured under the laws now or hereafter in effect in the United States and in any other jurisdiction, the same to be held and enjoyed by Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by Assignor had this Assignment of Patents and Trademarks not been made. Assignor hereby authorizes the U.S. Patent and Trademark Office, and, as appropriate, the corresponding officials in the several states as well as the corresponding officials in foreign countries, to record Assignee as the owner of the Patents and Trademarks assigned by Assignor to Assignee pursuant to this Assignment of Patents and Trademarks and issue in accordance with this Agreement all registrations of such Patents and Trademarks and all applications for any of the same, which are assigned to Assignee by this Agreement or which relate to the subject matter so assigned. Assignor further agrees to provide all assistance reasonably requested by Assignee to fulfill the purposes of this Assignment of Patents and Trademarks, including executing further consistent assurances, confirmation, assignments, transfers, and releases, and providing good faith testimony by affidavit, declaration, deposition, or other means. Assignor will not oppose or otherwise impede any effort by Assignee to enforce or procure registration for the Patents and Trademarks before any administrative, government or other tribunal.

Except to the extent that federal law preempts state law with respect to the matters covered hereby, this Assignment of Patents and Trademarks shall be governed by and construed in accordance with the laws of the State of New York without giving effect to the principles of conflicts of laws thereof.

[SIGNATURE PAGE TO FOLLOW]

IN WITNESS WHEREOF, Assignor has caused its duly authorized officer to execute this Assignment of Patents and Trademarks as of the date first above written.

NUTRITION 21, INC.

By: al Kurl
Name: Alan Kirschbaum
Title: CFO

NUTRITION 21, LLC

By: al Kurl
Name: Alan Kirschbaum
Title: CFO

ASSIGNEE

N21 ACQUISITION HOLDING, LLC

By: _____
Name:
Title:

SIGNATURE PAGE TO N21 ACQUISITION HOLDING, LLC INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

IN WITNESS WHEREOF, Assignor has caused its duly authorized officer to execute this Assignment of Patents and Trademarks as of the date first above written.

NUTRITION 21, INC.


By: _____
Name:
Title:

NUTRITION 21, LLC

By: _____
Name:
Title:

ASSIGNEE

N21 ACQUISITION HOLDING, LLC

By: 
Name: Michael Satow
Title: CEO

Annex A

Miscellaneous Patents

0	Product	Patent Code	Case No.	Title of Invention	Country	Status	Application No.	Patent No.	Filing Date	Date Issued	Expiration	Publication Number	Publication Date	
1	ASI	COM (3:3-1)	Use: Atherosclerosis	NUTR017A	ARGININE SILICATE COMPLEX	US	Issued	08/799784	5/70/90	2/12/1997	1/13/1998			
2	ASI	COM	Use: atherosclerosis, bone & cartilage (cont.)	NUTR017AFC	ARGININE SILICATE INOSITOL	US	Issued	09/367267	6156735	12/13/1999	12/5/2000	2/12/2017		
3	ASI	Mfg Method (gel) + Use (cont. '735, '970)		NUTR017CI	ARGININE SILICATE INOSITOL	US	Issued	09/730895	6344444	12/5/2000	2/5/2002	2/12/2017		
4	ASI	Mfg Method (gel) Use: Bone and cartilage		NUTR017QEP	ARGININE SILICATE INOSITOL	EP	Issued	98965010.9	1007096	2/11/1998	10/15/2003	2/11/2018	1007096	06/14/00
5	ASI	Use: Insulin Resistance; Use: Incr. NO		NUTR027DV1	ARGININE SILICATE INOSITOL	US	Issued	11/146620	7,576,132	6/6/2005	8/18/2009		2005- 10/20/05	
6	CH	COM		none	CHROMIUM-HISTIDINE	US	Issued	09/414645	6689383	10/8/1999	2/10/2004	9/12/2020		
7	CH	COM		none	CHROMIUM-HISTIDINE	AU	Issued	7999000		5/1/2002	5/5/2005		WO01/27123	
8	CH	COM		none	CHROMIUM-HISTIDINE	EP	Issued	20000970641		4/29/2002	12/20/2006		WO01/27123	
9	CN	Use: Cr/Nic + Pk. &/or Nic		AMBIINC.004A	CHROMIUM NICOTINATE	US	Issued	09/143256	5905075	8/28/1998	5/18/1999	8/28/2018		
10	CN	COM	Enteric-coated Cr/Nic	AMBIINC.004CP1	ENTERIC-COATED CHROMIUM	US	Issued	09/229463	6100250	1/12/1999	8/8/2000	8/28/2018		
11	CN	Use: Cr/Nic tyrosylase inhib, or salicin cont		AMBIINC.004CP2	CHROMIUM POLYNICOTINATE	US	Issued	09/291560	5980905	4/14/1999	11/9/1999	8/28/2018		
12	CN	Use: Cr/Nic + cyclooxygenase inhib or salicin cont		AMBIINC.1CP2C1	CHROMIUM POLYNICOTINATE	US	Issued	09/480468	6251888	1/10/2000	6/26/2001	8/28/2018		
13	CN	Use: Cr/Nic + Pk		AMBIINC.1CP1C1	CHROMIUM POLYNICOTINATE	US	Issued	09/480473	6100251	1/10/2000	8/8/2000	8/28/2018		
14	CN	Use: Cr/Nic + Pk		AMBIINC.4CPIC2	CHROMIUM POLYNICOTINATE	US	Issued	09/364664	6323192	8/8/2000	11/27/2001	8/28/2018		
15	CP	Use: Cr/Pk + Pk &/or Nic		AMBIINC.001A	CHROMIUM POLYNICOTINATE	US	Issued	09/144026	5948772	8/28/1998	9/7/1999	8/28/2018		
16	CP	COM & Use: Enteric-coated Cr/Pk		AMBIINC.001CP1	ENTERIC-COATED CHROMIUM	US	Issued	09/228701	6093711	1/12/1999	7/25/2000	8/28/2018		
17	CP	Use: Cr/Pk + cyclooxygenase inhib, or salicin cont		AMBIINC.001CP2	CHROMIUM POLYNICOTINATE	US	Issued	09/291561	6143301	4/14/1999	11/7/2000	8/28/2018		
18	CP	Use: Cr/Pk + cyclooxygenase inhib, or salicin cont		AMBIINC.001VPR1	CHROMIUM POLYNICOTINATE	FR	Issued	9814190	9814190	11/12/1998	12/15/2000	11/12/2018		
19	CP	Use: Cr/Pk + Pk		AMBIINC.1CP1C1	CHROMIUM POLYNICOTINATE	US	Issued	09/480472	6136317	1/10/2000	10/24/2000	8/28/2018		
20	CP	Use: Cr/Pk + Pk		AMBIINC.1CP1C2	CHROMIUM POLYNICOTINATE	US	Issued	09/696474	6251889	10/24/2000	6/26/2001	8/28/2018		
21	CP	Use: Cr/Pk + Nic		AMBIINC.1CP1C3	CHROMIUM POLYNICOTINATE	US	Issued	09/849864	6471998	5/4/2001	10/29/2002	8/28/2018	16580	8/23/2001
22	CP	Use: Cr/Pk + ard		AMBIINC.1CP2C2	CHROMIUM POLYNICOTINATE	US	Issued	09/849865	6432942	5/4/2001	8/13/2002	8/28/2018		
23	CP	Use: Cr/Pk + Pk		AMBIINC.1CP2C3	CHROMIUM POLYNICOTINATE	US	Issued	10/207748	6713469	7/25/2002	3/30/2004	8/28/2018	02-0197340	12/26/2002
24	CP	Use: Essentially Cr/Pk 1-10mg for blood glucose		NUTR013JA	HIGH-DOSE CHROMIC	US	Issued	08/440362	6239361	5/12/1995	12/1/2001	12/1/2018		
25	CP	Use: Essentially Cr/Pk 1-10mg for blood glucose		NUTR013VEP	HIGH DOSE CHROMIC	EP	Issued	9691595.1	825861	8/8/1996	11/6/2002	5/8/2016		03/04/98
26	CP	Use: Essentially Cr/Pk 1-10mg for blood glucose		NUTR013VJP	HIGH DOSE CHROMIC	JP	Issued	534219	3699124	8/8/1996	7/15/2005	5/8/2016		05/11/99
27	CP	Use: CP/HCA+carbamine+thiotin		NUTR019A	METHOD FOR PROMOTING	US	Issued	08/908820	5914326	8/8/1997	6/22/1999	8/8/2017		
28	CPB	Use: Cr/Pk (+10 mg Cr) + thiotin for lowering blood		NUTR019SA	HIGH-DOSE CHROMIUM BIOTIN	US	Issued	08/908819	5789401	8/8/1997	8/4/1998	8/8/2017		
29	CPB	Use: lowering blood glucose		NUTR019QAI	CHROMIUM BIOTIN TREATMENT	AU	Issued	87451208	754131	7/31/1998	12/5/2002	7/31/2018	751431	08/15/02
30	CPB	Use: lowering blood glucose		NUTR019QCA	CHROMIUM BIOTIN TREATMENT	CA	Issued	3297834	3297834	7/31/1998	9/30/2008	7/31/2018		
31	CPB	Use: lowering blood glucose		NUTR019QEZ	CHROMIUM BIOTIN TREATMENT	CZ	Issued	PV2000-324	298680	7/31/1998	11/13/2007	7/31/2018		03/14/01
32	CPB	Use: lowering blood glucose		NUTR019QDE	CHROMIUM BIOTIN TREATMENT	DE	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
33	CPB	Use: lowering blood glucose		NUTR019QEP	CHROMIUM BIOTIN TREATMENT	EP	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
34	CPB	Use: lowering blood glucose		NUTR019QES	CHROMIUM BIOTIN TREATMENT	ES	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
35	CPB	Use: lowering blood glucose		NUTR019QFR	CHROMIUM BIOTIN TREATMENT	FR	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
36	CPB	Use: lowering blood glucose		NUTR019QGB	CHROMIUM BIOTIN TREATMENT	GB	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
37	CPB	Use: lowering blood glucose		NUTR019QIE	CHROMIUM BIOTIN TREATMENT	IE	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
38	CPB	Use: lowering blood glucose		NUTR019QIL	USE OF CHROMIUM	IL	Issued	134163	134163	7/31/1998	8/16/2007	7/31/2018		05/15/07
39	CPB	Use: lowering blood glucose		NUTR019QIT	CHROMIUM BIOTIN TREATMENT	IT	Issued	98939167	1001793	7/31/1998	9/14/2005	7/31/2018	1001793	05/24/00
40	CPB	Use: lowering blood glucose		NUTR019QMX	CHROMIUM BIOTIN TREATMENT	MX	Issued	PA/a/2000/0012	217267	7/31/1998	10/29/2003	7/31/2018		
41	CPB	Use: lowering blood glucose		NUTR019QRAU	CHROMIUM BIOTIN TREATMENT	AU	Issued	2002302012	2002302012	7/31/1998	5/26/2005	7/31/2018		03/13/03
42	CPB	Use: glucose (cont. '401)		NUTR019SA	CHROMIUM BIOTIN TREATMENT	US	Issued	09/912472	RE39480	7/24/2001	1/23/2007	8/8/2017		
43	CPB	Use: Lipids		NUTR027VEP	CHROMIUM BIOTIN TREATMENT	EP	Issued	2721278.2	1397148	2/27/2002	9/20/2006	2/27/2022	1397148	03/17/04
44	Cr	Use: Cr as antidepressant for depression		none	METHOD OF TREATING	US	Issued	09/025081	5890036	2/19/1998	4/27/1999	2/19/2018		
45	Cr	Use: Cr (alone) for pre-menstrual syndrome		none	METHOD OF TREATING	US	Issued	09/025944	5972390	2/19/1998	10/26/1999	2/19/2018		
46	Cr	Use: Cr without antidepressant for depression		none	METHOD OF TREATING	US	Issued	09/025899	6034125	2/19/1998	3/7/2000	2/19/2018		
47	Cr	Use: Cr + SSRI for pre-menstrual syndrome		none	METHOD OF TREATING-PRE-	US	Issued	901841	5877171	7/28/1997	3/21/1999	7/28/2017		
48	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007A	METHODS AND COMPOSITIONS	US	Issued	09/957876	6809115	9/20/2001	10/26/2004	9/20/2021	02-0081315	6/27/2002
49	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007VE	CHROMIUM CONTAINING	DE	Issued	1975262.5	1357977	9/20/2001	7/21/2004	9/20/2021	1357977	11/5/2003
50	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007VEP	CHROMIUM CONTAINING	EP	Issued	1975262.5	1357977	9/20/2001	7/21/2004	9/20/2021	1357977	11/5/2003
51	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007VCS	CHROMIUM CONTAINING	ES	Issued	1975262.5	1357977	9/20/2001	7/21/2004	9/20/2021	1357977	11/5/2003
52	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007VFR	CHROMIUM CONTAINING	FR	Issued	1975262.5	1357977	9/20/2001	7/21/2004	9/20/2021	1357977	11/5/2003
53	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007VGB	CHROMIUM CONTAINING	GB	Issued	1975262.5	1357977	9/20/2001	7/21/2004	9/20/2021	1357977	11/5/2003
54	Cr/CLA	Use: Cr/CLA for body fat, glucose, ins sens, cholest		AMBIINC.007VIT	CHROMIUM CONTAINING	IT	Issued	1975262.5	1357977	9/20/2001	7/21/2004	9/20/2021	1357977	11/5/2003
55	CT	Use: Hypertension with antihypertensive drug		NUTR12CPCC	CALCIUM TAURATE AND USES	US	Issued	09/212019	6099869	12/15/1998	8/8/2000	4/18/2015		
56	CT	Use: dietary calcium supplementation		NUTR12CPCD	CALCIUM TAURATE AS A	US	Issued	09/459164	6203823	12/10/1999	3/20/2001	4/18/2015		
57	MT	Use: Parenteral treatment of chronic cardiac condi		NUTR012A	MAGNESIUM TAURATE AND	US	Issued	08/423891	5582839	4/18/1995	12/10/1996	4/18/2015		
58	MT	Use: Pre-eclampsia		NUTR012CPI	MAGNESIUM TAURATE FOR	US	Issued	08/554153	5776504	11/6/1995	7/7/1998	4/18/2015		
59	MT	Use: Parenteral treatment of stroke with anthron		NUTR012CPI	MAGNESIUM TAURATE AS AN	US	Issued	08/554151	5776498	11/6/1995	7/7/1998	4/18/2015		
60	MT	Use: Stroke with anti-thrombotic		NUTR012CPD	PHARMACEUTICAL	US	Issued	08/043770	5876757	10/31/1997	3/2/1999	10/31/2017		
61	ASI	Mfg Method (gel) Use: Bone and cartilage		NUTR017QIP	ARGININE SILICATE INOSITOL	JP	Pending	53466698		2/11/1998		2/11/2018	2001512443	08/21/01
62	ASI	Use: Insulin Resistance; Use: Incr. NO		NUTR027VCA	ARGININE SILICATE INOSITOL	CA	Pending	2494155		8/22/2003				
63	ASI	Use: Insulin Resistance; Use: Incr. NO		NUTR027VEP	ARGININE SILICATE INOSITOL	EP	Pending	3793307.A		8/22/2003			1534302	06/01/05
64	ASI	Use: Insulin Resistance; Use: Incr. NO		NUTR027VJP	ARGININE SILICATE INOSITOL	JP	Pending	2004-529869		8/22/2003				
65	ASI	Use: Insulin Resistance; Use: Incr. NO		NUTR027VMX	ARGININE SILICATE INOSITOL	MX	Pending	PA/a/2005/0019		8/22/2003				
66	CH	Use: blood glucose, lipids, body composition		NUTR031VPC	USE OF CHROMIUM HISTIDINATE	WO	Pending	PT/US2008/05		1/29/2008			2010000915	01/14/10
67	CH	COM		none	CHROMIUM-HISTIDINE	CA	Pending	2386790		4/4/2002			WO01/27123	
68	CH	COM		none	CHROMIUM-HISTIDINE	JP	Pending	20011530341		4/4/2002			WO01/27123	
69	CH	COM		none	CHROMIUM-HISTIDINE	WO	Pending						WO01/27123	4/19/2001
70	CP	Use: Essentially Cr/Pk 1-10mg for blood glucose		NUTR013VAR	HIGH DOSE CHROMIC	AR	Pending	P960102526		5/10/1996				12/26/98
71	CP+	Use: CP/HCA+carbamine+thiotin		NUTR019VCA	METHOD FOR PROMOTING	CA	Pending	2340629		7/31/1998				
72	CPB	Use: lowering blood glucose		NUTR019QBR	CHROMIUM BIOTIN TREATMENT	BR	Pending	P9811137-0		7/31/1998				
73	CPB	Use: lowering blood glucose		NUTR019QCN	CHROMIUM BIOTIN TREATMENT	CN	Pending	98807961.5		7/31/1998				

Nisin Related Patents

United States	Patent # 5,760,026
Australia Patent	Patent # 672384
New Zealand	Patent # 249007
New Zealand	Patent # 299034
New Zealand	Patent # 310798
United States	Patent # 5,762,948
United States	Patent # 5,985,823
United States	Patent # 5,135,910
United States	Patent # 5,763,395
United States	Patent # 5,559,096
United States	Patent # 5,958,873




Lysostaphin Related Patents

Australia	Patent # 2004201269
Germany	Patent # 1107722
European Patent Convention	Patent # 1107722
France	Patent # 1107722
United Kingdom	Patent # 1107722
United States of America	Patent # 6,028,051
United States of America	Patent # 6,569,830
United States of America	Patent # 7,122,514
United States of America	Patent # 7,078,377
Australia	Patent # 754806
Canada	Patent # 2297083
Germany	Patent # 1001804
European Patent Convention	Patent # 1001804
France	Patent # 1001804
United Kingdom	Patent # 1001804
United States of America	Patent # 6,156,332
United States of America	Patent # 5,804,549
United States of America	Patent # 5,866,539
United States of America	Patent # 5,858,962
Canada	Patent # 1340850
United States of America	Patent # 5,910,479
United States of America Published	11/445,289
Japan Pending	2000-503861

Trademarks in the Name of Nutrition 21, LLC

Trademark	Registration Number	Registration Date
CHROMAX	1,837,663	05/31/1994
CHROMAX	1,937,056	11/21/1995
CHROMAX II	1,590,459	04/10/1990
NUTRITION 21	2,024,986	12/24/1996
SELENOMAX	2,005,236	10/01/1996
SELENO PURE	2,626,190	09/24/2002
ZENERGEN	2,940,546	04/12/2005
ZINMAX	2,024,537	12/17/1996

Trademarks in the Name of Nutrition 21, Inc.

Trademark	Registration No. (Application Number)	Registration Date (Application Date)
	2,674,646	01/14/2003
	2,674,651	01/14/2003
	2,674,652	01/14/2003
CORE4LIFE CHROMAX	(77/069,235)	(12/21/2006)
DIACHROME	2,854,190	06/15/2004
DIACHROME	2,948,444	05/10/2005
Diachrome	(77/209,714)	(06/19/2007)
PERFECT 3	(78/904,417)	(06/09/2006)

Foreign Trademarks in the Name of Nutrition 21, Inc.

Trademark	Country	Registration No. (Application Number)	Registration Date (Application Date)
BRITE BITES	CTM	1,131,952	02/01/2001
CHROMAX	Canada	TMA483841	10/09/1997
CHROMAX	CTM	3,244,829	07/04/2006
SELENOMAX	CTM	(5,605,845)	(01/10/2007)
SELENOMAX	South Africa	(2007/03416)	(02/21/2007)
SWEET SUPPORT	CTM	1,308,394	12/22/2000



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 25, 2012

PTAS
KNOBBE, MARTENS. OLSON & BEAR, LLP
2040 MAIN STREET, 14TH FLOOR
IRVINE, CA 92614



700488104

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/19/2012

REEL/FRAME: 004806/0001
NUMBER OF PAGES: 10

BRIEF: ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL
DOCKET NUMBER: NUTRI.OOOGEN

ASSIGNOR:
NUTRITION 21, INC.

DOC DATE: 11/22/2011
CITIZENSHIP: NEW YORK
ENTITY: CORPORATION

ASSIGNEE:
N21 ACQUISITION HOLDING, LLC
4 MANHATTANVILLE RD.
SUITE 202
PURCHASE, NEW YORK 10577

CITIZENSHIP: NEW YORK
ENTITY: CORPORATION

Received Orange County
Cocketing

JUN 29 2012

Knobbe, Martens, Olson &
Bear LLP

TRADEMARK
REEL: 004817 FRAME: 0035

SERIAL NUMBER: 76366490
REGISTRATION NUMBER: 2674646

FILING DATE: 02/04/2002
ISSUE DATE: 01/14/2003

MARK: CONTROL EATING BALANCE BODY COMPOSITION
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS AND DESIGN

SERIAL NUMBER: 76366677
REGISTRATION NUMBER: 2674651

FILING DATE: 02/04/2002
ISSUE DATE: 01/14/2003

MARK: CONTROL EATING BALANCE BODY COMPOSITION
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS AND DESIGN

SERIAL NUMBER: 76366766
REGISTRATION NUMBER: 2674652

FILING DATE: 02/04/2002
ISSUE DATE: 01/14/2003

MARK: CONTROL EATING BALANCE BODY COMPOSITION
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS AND DESIGN

SERIAL NUMBER: 76126043
REGISTRATION NUMBER: 2854190

FILING DATE: 09/11/2000
ISSUE DATE: 06/15/2004

MARK: DIACHROME
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN TYPED FORM

SERIAL NUMBER: 76170416
REGISTRATION NUMBER: 2948444

FILING DATE: 11/22/2000
ISSUE DATE: 05/10/2005

MARK: DIACHROME
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN TYPED FORM

SERIAL NUMBER: 77069235
REGISTRATION NUMBER: 3395499

FILING DATE: 12/21/2006
ISSUE DATE: 03/11/2008

MARK: CORE4LIFE CHROMAX
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN BLOCK FORM

SERIAL NUMBER: 77209714
REGISTRATION NUMBER: 3362195

FILING DATE: 06/19/2007
ISSUE DATE: 01/01/2008

MARK: DIACHROME
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS AND DESIGN

004806/0001 PAGE 3

SERIAL NUMBER: 78904417
REGISTRATION NUMBER: 3309819

FILING DATE: 06/09/2006
ISSUE DATE: 10/09/2007

MARK: PERFECT 3
DRAWING TYPE: WORDS, LETTERS, OR NUMBERS IN BLOCK FORM

MARY BENTON, EXAMINER
ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION

Client Code: NUTRI.000GEN

RECORDATION FORM COVER SHEET

TRADEMARKS ONLY
06/19/2012
700488104

To the Director, U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies): (List using letters or numbers for multiple parties)</p> <p>Nutrition 21, Inc.</p> <p>() Individual () General Partnership () Association () Limited Partnership () Other: (X) Corporation of: NY</p> <p>Additional name(s) of conveying party(ies) attached? () Yes (X) No</p>	<p>2. Name and address of receiving party(ies):</p> <p>Name: N21 Acquisition Holding, LLC Internal Address: Suite 202 Street Address: 4 Manhattanville Rd. City: Purchase State: NY ZIP: 10577</p> <p>() Individual () General Partnership () Association () Limited Partnership () Other: (X) Corporation of: NY</p> <p>If assignee is not domiciled in the United States, a domestic representative designation is attached: () Yes (X) No</p> <p>Additional name(s) and address(es) attached? () Yes (X) No</p>
<p>3. Nature of conveyance:</p> <p>(X) Assignment () Security Agreement () Merger () Change of Name () Other:</p> <p>Execution Date: (List as in section 1 if multiple signatures) November 22, 2011</p>	<p>4. Application number(s) or registration number(s):</p> <p>a. Trademark Application No(s):</p> <p>b. Trademark Registration No(s): 2,674,646; 2,674,651; 2,674,652; 2,854,190; 2,948,444; 3,395,499; 3,362,195; 3,309,819</p> <p>Additional numbers attached? () Yes (X) No</p>
<p>5. Party to whom correspondence concerning document should be mailed:</p> <p>Customer No. 20,995 Address: Knobbe, Martens, Olson & Bear, LLP 2040 Main Street, 14th Floor Irvine, CA 92614 Return Fax: (949) 760-9502 Attorney's Docket No.: NUTRI.000GEN</p>	<p>6. Total number of applications and registrations involved: 8</p> <p>7. Total fee (37 CFR 1.21(h)): \$320 (X) Authorized to be charged to deposit account</p>
<p>8. Deposit account number: 11-1410</p> <p>Please charge this account for any additional fees which may be required, or credit any overpayment to this account.</p>	
<p>9. Statement and signature.</p> <p>To the best of my knowledge and belief, the foregoing information is true and correct, and any attached copy is a true copy of the original document.</p> <p>Kathleen R. Mekjian <u><i>Kathleen R. Mekjian</i></u> <u>June 19, 2012</u> Name of Person Signing Signature Date</p> <p>Total number of pages including cover sheet, attachments and document: 10</p>	

CH \$215.00 111410 2674646

Documents transmitted via Facsimile to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services
Director, U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
Facsimile Number: (571) 273-0140